{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:32:14Z","timestamp":1759073534980},"reference-count":46,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.neuropharm.2013.05.031","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T04:18:26Z","timestamp":1376453906000},"page":"356-364","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity"],"prefix":"10.1016","volume":"75","author":[{"given":"Rongyin","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.05.031_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00210-007-0154-x","article-title":"Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic","volume":"375","author":"Abekawa","year":"2007","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(95)00292-S","article-title":"Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine","volume":"283","author":"Arnt","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1098-2396(199908)33:2<118::AID-SYN2>3.0.CO;2-L","article-title":"Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs","volume":"33","author":"Atkins","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S1461145709990824","article-title":"Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors","volume":"13","author":"Choi","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.pbb.2005.05.011","article-title":"Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas","volume":"81","author":"Doat-Meyerhoefer","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib6","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.neuropharm.2011.08.026","article-title":"Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration","volume":"62","author":"Elsworth","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pbb.2012.09.013","article-title":"Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: further test of the motivational salience hypothesis","volume":"103","author":"Feng","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbr.2012.10.009","article-title":"Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm","volume":"238","author":"Feng","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/syn.21551","article-title":"Involvement of 5-HT(2A) receptor and alpha(2)-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow","volume":"66","author":"Franberg","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","article-title":"Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia","volume":"196","author":"Franberg","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","article-title":"Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice","volume":"129","author":"Gleason","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3928\/02793695-20110311-99","article-title":"Update on newer antipsychotic drugs","volume":"49","author":"Howland","year":"2011","journal-title":"J.\u00a0Psychosoc Nurs. Ment. Health Serv."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib13","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/npp.2008.20","article-title":"Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus","volume":"33","author":"Huang","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pnpbp.2007.09.008","article-title":"Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague\u2013Dawley rats: a locomotor activity and gene induction study","volume":"32","author":"Kalinichev","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in\u00a0vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.npp.1301110","article-title":"Time course of the antipsychotic effect and the underlying behavioral mechanisms","volume":"32","author":"Li","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/FBP.0b013e32832a8f66","article-title":"An investigation of the behavioral mechanisms of antipsychotic action using a drug\u2013drug conditioning paradigm","volume":"20","author":"Li","year":"2009","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FBP.0b013e3283243008","article-title":"Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus","volume":"20","author":"Li","year":"2009","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00702-011-0722-6","article-title":"Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT(2A\/2C) receptors","volume":"119","author":"Li","year":"2012","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-010-1925-5","article-title":"Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning","volume":"212","author":"Li","year":"2010","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","article-title":"Asenapine effects in animal models of psychosis and cognitive function","volume":"206","author":"Marston","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib22","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1016\/0014-2999(95)00333-G","article-title":"Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors","volume":"280","author":"Maurel-Remy","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbr.2010.05.043","article-title":"Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat","volume":"214","author":"McLean","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0269881109102546","article-title":"Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism","volume":"24","author":"Mead","year":"2010","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd3027","article-title":"Asenapine","volume":"8","author":"Meltzer","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib27","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1046\/j.1460-9568.1999.00858.x","article-title":"Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat","volume":"11","author":"Millan","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/syn.20220","article-title":"Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects","volume":"59","author":"Moran-Gates","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/npp.2012.213","article-title":"Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model","volume":"38","author":"Qiao","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(98)00023-6","article-title":"Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity","volume":"9","author":"Redmond","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00213-010-2091-5","article-title":"Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism","volume":"214","author":"Snigdha","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/FBP.0b013e328358590d","article-title":"Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia","volume":"23","author":"Sparkman","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejphar.2008.11.036","article-title":"Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs","volume":"602","author":"Sun","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2010.02.024","article-title":"Iptakalim: a potential antipsychotic drug with novel mechanisms?","volume":"634","author":"Sun","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/FBP.0b013e32835651ea","article-title":"Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval","volume":"23","author":"Swalve","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00213-008-1364-8","article-title":"Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions","volume":"202","author":"Tait","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-008-1098-7","article-title":"Differential regional and dose-related effects of asenapine on dopamine receptor subtypes","volume":"198","author":"Tarazi","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0269881108095704","article-title":"Asenapine induces differential regional effects on serotonin receptor subtypes","volume":"24","author":"Tarazi","year":"2010","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib40","article-title":"The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania","author":"Tarazi","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2009.45.12.1421561","article-title":"Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania","volume":"45","author":"Tarazi","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.neuropharm.2013.05.031_bib42","first-page":"711","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment","volume":"297","author":"Tarazi","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pbb.2010.12.018","article-title":"Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence","volume":"98","author":"Zhang","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/FBP.0b013e32834ecac4","article-title":"Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine","volume":"23","author":"Zhang","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pbb.2012.08.021","article-title":"Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity","volume":"103","author":"Zhao","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.05.031_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pnpbp.2012.03.007","article-title":"Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion","volume":"38","author":"Zhao","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T00:28:07Z","timestamp":1539476887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813002451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":46,"alternative-id":["S0028390813002451"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.031","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}